ProQR Therapeutics N.V. (PRQR)
NASDAQ: PRQR · Real-Time Price · USD
2.560
-0.020 (-0.78%)
At close: Feb 21, 2025, 4:00 PM
2.600
+0.040 (1.56%)
After-hours: Feb 21, 2025, 5:11 PM EST
ProQR Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for ProQR Therapeutics stock have an average target of 8.17, with a low estimate of 2.00 and a high estimate of 14. The average target predicts an increase of 219.14% from the current stock price of 2.56.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for ProQR Therapeutics stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 3 | 3 | 3 | 3 | 4 |
| Buy | 3 | 0 | 0 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 4 | 4 | 5 | 5 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Jones Trading | Jones Trading | Strong Buy Initiates $11 | Strong Buy | Initiates | $11 | +329.69% | Feb 12, 2025 |
| JMP Securities | JMP Securities | Buy Reiterates $8 | Buy | Reiterates | $8 | +212.50% | Dec 12, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $4 | Strong Buy | Maintains | $4 | +56.25% | Dec 12, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +290.62% | Dec 12, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $5 → $10 | Strong Buy | Maintains | $5 → $10 | +290.62% | Nov 8, 2024 |
Financial Forecast
Revenue This Year
20.45M
from 6.59M
Increased by 210.18%
Revenue Next Year
27.25M
from 20.45M
Increased by 33.25%
EPS This Year
-0.32
from -0.35
EPS Next Year
-0.41
from -0.32
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 30.5M | 64.6M | 20.0M | |||
| Avg | 20.5M | 27.3M | 10.8M | |||
| Low | 13.8M | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 361.8% | 215.7% | -26.8% | |||
| Avg | 210.2% | 33.2% | -60.3% | |||
| Low | 109.6% | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | -0.21 | -0.17 | -0.38 |
| Avg | -0.32 | -0.41 | -0.54 |
| Low | -0.36 | -0.59 | -0.67 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.